RPA3: A Potential Drug Target and Biomarker for Cancer (G6119)

Target Name: RPA3

NCBI ID: G6119

RPA3

RPA3: A Potential Drug Target and Biomarker for Cancer

RPA3 (RF-A protein 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-protein binding proteins, which are involved in the regulation of gene expression. RPA3 is composed of a unique nucleotide-rich region, a transmembrane region, and an optional cytoplasmic tail. The function of RPA3 is not well understood, but it is thought to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival.

Drug Target Potential

RPA3 is a potential drug target due to its unique structure and the involvement of cellular processes that are often targeted by therapeutic agents. One of the key challenges in targeting RPA3 is its expression pattern, which is known to be highly expressed in a variety of tissues in tumor cells. This makes it difficult to selectively target RPA3, and also increases the risk of off-target effects. However, recent studies have identified potential biomarkers for RPA3, which may be useful for the diagnosis and monitoring of RPA3-positive tumors.

One of the potential drug targets for RPA3 is the inhibition of RPA3 function. This can be achieved by small molecule inhibitors, such as inhibitors of the RNA-protein binding activity of RPA3, or by monoclonal antibodies that specifically target RPA3. These approaches have been shown to be effective in preclinical studies in cell models of cancer. For example, a small molecule inhibitor, N1-1, was shown to inhibit the activity of RPA3 and reduce the migration of cancer cells in a xenograft model of colon cancer.

Another approach to targeting RPA3 is the use of RNA-based therapies. RNA-based therapies are a promising approach for the treatment of cancer, as they can be designed to specifically target the expression of genes in cancer cells. One example of an RNA- based therapy for RPA3 is designed to target the expression of RPA3 in cancer cells using small interfering RNA (siRNA). This approach has been shown to be effective in preclinical studies, where it was shown to reduce the expression of RPA3 in cancer cells and inhibit their migration.

Biomarker Potential

RPA3 is a potential biomarker for cancer, as its expression is known to be elevated in many types of cancer. This makes RPA3 an attractive target for cancer diagnostics and monitoring. One approach to identifying RPA3-positive cancer cells is to use fluorescence in situ hybridization (FISH), a technique that allows for the detection of specific DNA sequences in live cells. This technique can be used to detect RPA3-positive cancer cells in a variety of tissues, including breast, lung, and colon cancer.

Another approach to identifying RPA3-positive cancer cells is to use qRT-PCR, a technique that is used to measure the expression of specific genes in cells. This technique can be used to detect RPA3-positive cancer cells in a variety of tissues, including breast, lung, and colon cancer.

Conclusion

RPA3 is a protein that is expressed in various tissues of the body and is thought to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival. As a potential drug target, RPA3 is a promising target for the treatment of cancer, with recent studies showing that inhibition of RPA3 function or the use of RNA-based therapies may be effective in preclinical models of cancer. Additionally, RPA3 is also a potential biomarker for cancer, as its expression is known to be elevated in many types of cancer. Further research is needed to fully understand the role of RPA3 in cancer biology and to develop effective therapies for RPA3-positive cancer cells.

Protein Name: Replication Protein A3

Functions: As part of the heterotrimeric replication protein A complex (RPA/RP-A), binds and stabilizes single-stranded DNA intermediates that form during DNA replication or upon DNA stress. It prevents their reannealing and in parallel, recruits and activates different proteins and complexes involved in DNA metabolism. Thereby, it plays an essential role both in DNA replication and the cellular response to DNA damage (PubMed:9430682). In the cellular response to DNA damage, the RPA complex controls DNA repair and DNA damage checkpoint activation. Through recruitment of ATRIP activates the ATR kinase a master regulator of the DNA damage response (PubMed:24332808). It is required for the recruitment of the DNA double-strand break repair factors RAD51 and RAD52 to chromatin, in response to DNA damage. Also recruits to sites of DNA damage proteins like XPA and XPG that are involved in nucleotide excision repair and is required for this mechanism of DNA repair (PubMed:7697716). Also plays a role in base excision repair (BER), probably through interaction with UNG (PubMed:9765279). Also recruits SMARCAL1/HARP, which is involved in replication fork restart, to sites of DNA damage. May also play a role in telomere maintenance. RPA3 has its own single-stranded DNA-binding activity and may be responsible for polarity of the binding of the complex to DNA (PubMed:19010961). As part of the alternative replication protein A complex, aRPA, binds single-stranded DNA and probably plays a role in DNA repair. Compared to the RPA2-containing, canonical RPA complex, may not support chromosomal DNA replication and cell cycle progression through S-phase. The aRPA may not promote efficient priming by DNA polymerase alpha but could support DNA synthesis by polymerase delta in presence of PCNA and replication factor C (RFC), the dual incision/excision reaction of nucleotide excision repair and RAD51-dependent strand exchange (PubMed:19996105)

The "RPA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets